



(51) International Patent Classification:

A61K 39/00 (2006.01) A61K 39/44 (2006.01)
A61K 39/395 (2006.01) A61K 47/50 (2017.01)
C07K 16/40 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2022/020697

(22) International Filing Date:

17 March 2022 (17.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/162,635 18 March 2021 (18.03.2021) US
63/301,574 21 January 2022 (21.01.2022) US

(71) Applicant: SEAGEN INC. [US/US]; 21823 30th Drive SE, Bothell, Washington 98021 (US).

(72) Inventors: RINCON ARANO, Hector De Jesus; 21823 30th Drive SE, Bothell, Washington 98021 (US). RIOR-DAN ANDERSON, Sarah Ann; 21823 30th Drive SE, Bothell, Washington 98021 (US). SCHERER, Erin Margaret; 21823 30th Drive SE, Bothell, Washington 98021 (US). WESTENDORF, Lori; 21823 30th Drive SE, Both-

ell, Washington 98021 (US). BINDMAN, Noah; 21823 30th Drive SE, Bothell, Washington 98021 (US). OKE-LEY, Nicole; 21823 30th Drive SE, Bothell, Washington 98021 (US). SENTER, Peter; 21823 30th Drive SE, Bothell, Washington 98021 (US). AWASTHI, Divya; 21823 30th Drive SE, Bothell, Washington 98021 (US).

(74) Agent: KIM-SZPAJDA, Jane et al.; Seagen Inc., 21823 30th Drive SE, Bothell, Washington 98021 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: ANTI-ALPP/ALPL2 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES




FIGURE 4

(57) Abstract: Antigen binding proteins such as antibodies and fragments thereof that bind ALPP and/or ALPL2 are provided. Nucleic acids encoding such antigen binding proteins and vectors and cells useful in preparing such antigen binding proteins are also provided. The antigen binding proteins are useful in a variety of methods, including the treatment of ovarian cancer.

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*